Timing Follow-up Marker A1c Why it matters Shows longer-term glucose control before and during IGF-related protocols
Clinical Scenarios Favoring Monotherapy IGF-1 is 20-30% below the age-adjusted reference range but not severely deficient The patient is age 30% below range) | | Age | 50 | | Prior response to sermorelin | IGF-1 normalized at 12 weeks | IGF-1 unchanged or minimally changed | | Pituitary reserve assessment | Normal GH stimulation test | Subnormal peak GH on stimulation | | Cost tolerance | Lower | Higher | | Concurrent anabolic goals | Baseline wellness | Body recomposition, recovery | Dosing the Sermorelin + CJC-1295 Protocol No published RCT has evaluated the combination protocol head-to-head against monotherapy in adults
The typical decrease in weight and metabolic markers is the primary yardstick for comparing these two medications
Potentially Boosts Fat Metabolism and Fights Diabetes Emerging studies suggest that IGF-1 LR3 may play a role in enhancing fat metabolism, presenting a potential avenue for research in diabetes management
Helpful links: State of California, Compounding Regulations Information FDA Human Drug Compounding Information Joint Commission: Pharmacy Rules/Regulations by State for Compliance with USP 797 California Board of Pharmacy Contacts FDA Inspections of Compounding Outsourcing Facilities YouTube Video FDA on Human Drug Compounding
Brand Reputation and Reviews : Choose reputable brands known for high-quality, reliable batteries
.png)
